Clinical Context
A patient is referred for targeted genetic analysis after an initial pharmacogenomic assay yields an inconclusive CYP2D6 result. The patient is typically an adult or pediatric patient taking or being considered for medications metabolized by CYP2D6 (for example, certain antidepressants, opioids, beta-blockers, or tamoxifen) where genotype-directed prescribing may affect safety or efficacy. A clinician (often a clinical pharmacologist, psychiatrist, oncologist, pain specialist, or primary care provider) orders the follow‑up test 0072U to resolve a suspected CYP2D6–2D7 hybrid allele that interfered with the initial genotype call.
Workflow:
-
The ordering clinician documents indication and relevant medications in the chart and sends a specimen (usually blood or saliva) to the performing laboratory.
-
The laboratory receives the specimen, verifies patient identifiers, and performs targeted sequence analysis using the proprietary Mayo Clinic Laboratory method specifically described by 0072U to detect CYP2D6–2D7 hybrid alleles.
-
The laboratory interprets results and issues a report that clarifies the CYP2D6 genotype/allele status, including presence or absence of hybrid alleles and predicted metabolizer phenotype.
-
The ordering clinician reviews the report and incorporates the clarified genotype into medication selection or dosing decisions and documents the pharmacogenomic result in the EHR with problem list or medication reconciliation notes.
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|
0070U | CYP2D6 Gene Targeted Sequence Analysis (initial assay) | Initial pharmacogenomic assay; 0072U is a follow‑up when 0070U is inconclusive for CYP2D6 genotype due to possible hybrid alleles. |
81225 | CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) gene analysis, common variants (eg, *2, *3, *4, *5, *6), single or multiple variants; genotyping by targeted sequence analysis | Commonly used CYP2D6 genotyping code for targeted variant panels; may be used before or instead of PLA codes depending on laboratory methods.
81479 | Unlisted molecular pathology procedure | Used in workflows when a specific PLA code is not available, or for custom molecular testing adjuncts to targeted sequence analysis.
88360 | Immunohistochemistry or special stains interpreted by a pathologist (qualitative or semiquantitative) | Not directly related but appears in some molecular pathology workflows when tissue-based ancillary studies are required.
G0452 | Pharmacogenetic testing, multiple gene analysis (list separately in addition to primary test) | Applicable in broader pharmacogenomic panels where CYP2D6 testing is part of multi-gene reports.